Loading clinical trials...
Loading clinical trials...
A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
AT9283
Locations
6
Canada
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Atlantic Health Sciences Corporation
Saint John, New Brunswick, Canada
QEII Health Sciences Center
Halifax, Nova Scotia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Start Date
February 15, 2011
Primary Completion Date
October 29, 2014
Completion Date
November 27, 2015
Last Updated
August 4, 2023
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
NCIC Clinical Trials Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions